Highlights

  • Ceryvyn is developing CYV-101 for lymphangioleiomyomatosis (LAM), a rare progressive lung disease.
  • The company adopted its current name and ASX:CYV code in July 2026.
  • The CYV-101 program focuses on signalling involving VEGF-C, VEGF-D and VEGFR-3.
  • Its 2026 development work included nebulisation feasibility and broader preclinical planning.
  • Clinical outcomes, development costs and regulatory requirements remain material uncertainties.

Ceryvyn Therapeutics Limited (ASX:CYV) is an Australian biotechnology company developing a biologic treatment for lymphangioleiomyomatosis (LAM), a rare disease that progressively affects lung function. Its lead candidate, CYV-101, is intended to intervene in biological pathways associated with abnormal lymphatic activity. During 2026, the company refined its development plans and established the corporate structure under which its LAM program will proceed.

CYV-101 Targets a Distinct LAM Pathway

LAM involves abnormal cell behaviour that can damage lung tissue and compromise breathing. Ceryvyn Therapeutics (ASX:CYV) is studying CYV-101, a fusion protein designed to bind vascular endothelial growth factors VEGF-C and VEGF-D. Blocking these signals is intended to limit their interaction with the VEGFR-3 receptor, a pathway associated with lymphatic changes in LAM.

This proposed mechanism is different from the mTOR pathway addressed by established treatment. However, a distinct biological approach does not itself demonstrate a clinical benefit. The potential effect of CYV-101 on symptoms, lung function and disease progression needs to be established through an appropriate development program.

2026 Corporate Changes and Research Priorities

After its securities were reinstated to ASX Quotation on 3 June 2026, the Business changed its name from Opthea Limited to Ceryvyn Therapeutics Limited and adopted the ASX:CYV code in July. These steps accompanied a renewed focus on the LAM treatment program.

In its July 2026 quarterly activities disclosure, ASX:CYV reported progress with preclinical feasibility studies investigating nebulised delivery of CYV-101. The company also outlined work with specialist advisers and scientific experts to inform the LAM development pathway. These activities concern formulation, delivery and clinical planning rather than a demonstrated treatment effect in LAM patients.

CYV-101 was previously studied in another therapeutic area, providing prior experience with the molecule. Nevertheless, earlier data in a different condition cannot establish its effectiveness in LAM, and inhaled delivery introduces separate formulation and testing considerations.

Financial and Clinical Execution Considerations

The timing and cost of therapeutic development depend on studies, Manufacturing requirements and regulator feedback. For Ceryvyn Therapeutics (ASX:CYV), a central operational issue is whether its proposed delivery approach achieves suitable performance and supports a defined clinical study plan. Translating preclinical observations into clinical evidence can require additional work, particularly for an uncommon disease.

Funding is another consideration. Research, manufacturing and trial preparation may require substantial expenditure before a candidate generates commercial revenue. ASX:CYV therefore faces uncertainty around program costs, future Capital requirements and the sequence of development milestones. No specific financial runway or clinical completion date is assumed here.

Key Insights

Ceryvyn Therapeutics (ASX:CYV) is pursuing a targeted biological approach to LAM through CYV-101. The 2026 record highlights its ASX reinstatement, corporate transition and preclinical delivery work. The distinction between research progress and confirmed therapeutic benefit remains important: clinical efficacy, patient safety in the proposed setting, manufacturing feasibility and financing will determine subsequent development decisions.